Hologic showcases new Mammosite at ASTRO 2009
A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting.
A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting. The multi-lumen configuration, cleared by the FDA on August 27, allows oncologists to shape the radiation dose. It is the latest enhancement of the basic design, commercially launched some seven years ago. MammoSite delivers targeted radiation therapy directly to the area where cancer is most likely to recur. A full course of radiation can be delivered in just five days. The approach minimizes radiation exposure of healthy tissue surrounding the target site, minimizing side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 3rd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 3rd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 3rd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
